(3Z)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]-1H-indol-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (3Z)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]-1H-indol-2-one
• 化学式: C₁₆H₁₃NO₃
• 分子量: 267.284
• InChiKey: BQINENDEUIXMAZ-WQLSENKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  靛红 在 哌啶 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 8.0h， 生成 (3Z)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]-1H-indol-2-one
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 3-(Substituted-benzylidene)-1,3-dihydro-indolin Derivatives as Human Protein Kinase CK2 and p60c-Src Tyrosine Kinase Inhibitors

  摘要：

  人类蛋白激酶 CK2 是一种无处不在的丝氨酸/苏氨酸激酶，通常存在于由两个催化亚基（α 和/或 α′）和两个调节亚基 β 组成的四聚体复合物中。尽管越来越多的证据表明，CK2 除了参与一系列复杂的细胞功能外，还参与细胞活力、细胞增殖和肿瘤转化。本研究测试了一系列 3-（取代-亚苄基）-1,3-二氢-吲哚啉-2-硫酮衍生物和相应的吲哚啉-2-酮同系物在体外对人类重组蛋白激酶 CK2 的抑制作用。将这些化合物的功效与它们对 p60c-Src 酪氨酸激酶的抑制结果进行了比较。结果发现，在抑制 CK2 和 p60c-Src 酪氨酸激酶方面，3-（取代-亚苄基）-1,3-二氢-吲哚啉-2-硫酮衍生物比吲哚啉-2-酮同系物更有效。

  DOI：

  10.1248/bpb.30.715

文献信息

• [EN] NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES<br/>[FR] NOUVELLE UTILISATION THERAPEUTIQUE DE DERIVES D'INDOLINONE
  申请人：LEO PHARMA AS

  公开号：WO2005058309A1

  公开（公告）日：2005-06-30

  Certain oxindole compounds have been found to be effective in experimentally induced autoimmune encephalitis and are therefore suggested for the preparation of a medicament for the prevention, treatment or amelioration of multiple sclerosis, or to delay the onset of or reduce the relapse rate in multiple sclerosis.

  某些氧吲哚化合物已被发现在实验诱导的自身免疫性脑炎中具有有效性，因此建议用于制备用于预防、治疗或改善多发性硬化症的药物，或延缓多发性硬化症的发作或减少复发率。
• Novel therapeutic use
  申请人：Bouerat Duvold Maud Elysa Laetitia

  公开号：US20070167488A1

  公开（公告）日：2007-07-19

  Certain oxindole compounds have been found to be effective in experimentally induced autoimmune encephalitis and are therefore suggested for the preparation of a medicament for the prevention, treatment or amelioration of multiple sclerosis, or to delay the onset of or reduce the relapse rate in multiple sclerosis.

  某些恶唑酮化合物已被发现在实验性自身免疫脑炎中具有疗效，因此建议用于制备用于预防、治疗或改善多发性硬化症的药物，或者延迟多发性硬化症的发作或减少复发率。
• TGF-beta enhancing compositions for cartilage repair and methods related thereto
  申请人：EMORY UNIVERSITY

  公开号：US10322125B2

  公开（公告）日：2019-06-18

  This disclosure relates to compounds and compositions for cartilage repair and methods related thereto. In certain embodiments, the disclosure relates to methods of inducing cartilage growth and regeneration comprising administering an effective amount of a composition comprising a compound disclosed herein to the subject or implanting a cartilage matrix comprising a compound disclosed herein in the subject. In certain embodiments, the compound is used locally such as injection at any desired site of cartilage formation.

  本公开涉及用于软骨修复的化合物和组合物及其相关方法。在某些实施方案中，本公开涉及诱导软骨生长和再生的方法，包括向受试者施用有效量的包含本文公开的化合物的组合物，或在受试者体内植入包含本文公开的化合物的软骨基质。在某些实施方案中，该化合物用于局部，如注射到软骨形成的任何所需部位。
• Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies
  作者：Sureyya Olgen、Eiichi Akaho、Dogu Nebioglu

  DOI：10.1016/j.farmac.2005.01.015

  日期：2005.6

  A series of 3-(substituted-benzylidene)-1, 3-dihydro-indolin-2-thione derivatives were synthesized as modified congeners of 3-(substituted-benzylidene)-1, 3-dihydro-indolin-2-one series. All the synthesized compounds were examined for their in vitro anti-tyrosine kinase activity against p60c-Src. The activity results revealed that compounds (Z)-3-(4'-Dimethylamino-benzylidene)-1, 3-dihydro-indolin-2-thione (12) (E)-3-(2', 6'-Dichloro-benzylidene)-1, 3-dihydro-indolin-2-thione (13) and (E)-3-(3'-Hydroxy-4'-methoxy-benzylidene)-1, 3-dihydro-indolin-2-thione (19) exhibited anti-tyrosine kinase activity with IC50 value of 21.91, 21.20 and 30.92 microM, respectively. These results are comparable to PP1 [1-tert-Butyl-3-p-tolyl-1H-pyrazolo[3, 4-d]pyrimidine-4-yl-amine] (IC50=0.17 microM), which is reported as a potent and selective p60c-Src tyrosine kinase inhibitor. Some thio congeners are found to be more potent than oxo derivatives; however, no significant correlation was observed between the activity profiles of these two series. Docking program was used to investigate the docking mode of each compound at the active site. Among all of the compounds, only (Z)-3-(2'-Chloro-benzylidene)-1, 3-dihydro-indolin-2-one (8) and (E)-3-(3'-Nitro-benzylidene)-1, 3-dihydro-indolin-2-thione (16) were docked at the active site where the PP1 was embedded.
• NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES
  申请人：LEO PHARMA A/S

  公开号：EP1696906A1

  公开（公告）日：2006-09-06